Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Proteolysis Targeting Chimera Degraders of the METTL3–14 m6A-RNA Methyltransferase
Francesco Errani, Annalisa Invernizzi, Marcin Herok, et al.
JACS Au (2024) Vol. 4, Iss. 2, pp. 713-729
Open Access | Times Cited: 14

Showing 14 citing articles:

Small molecule inhibitors targeting m6A regulators
Guotai Feng, Yongya Wu, Yuan Hu, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 11
Lomitapide: Targeting METTL3 to Overcome Osimertinib Resistance in NSCLC Through Autophagy Activation
Xiaohui Du, Congcong Zhang, Ying Li, et al.
MedComm – Oncology (2025) Vol. 4, Iss. 1
Open Access | Times Cited: 1
METTL14‐mediated m6A modification of ZFP14 inhibits clear cell renal cell carcinoma progression via promoting STAT3 ubiquitination
Zhuonan Liu, Tianshui Sun, Zhe Zhang, et al.
Clinical and Translational Medicine (2025) Vol. 15, Iss. 2
Open Access
Development of 3-Arylaminothiophenic-2-carboxylic Acid Derivatives as New FTO Inhibitors Showing Potent Antileukemia Activities
Deyan Zhang, Lu Liu, Ming Li, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117444-117444
Closed Access
Epigenetic Targets and Their Inhibitors in the Treatment of Idiopathic Pulmonary Fibrosis
Xiaohui Miao, Pan Liu, Yangyang Liu, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117463-117463
Closed Access
Recent Advances in Medicinal Chemistry Strategies for the Development of METTL3 Inhibitors
G. Li, Wei Chen, Dan Liu, et al.
European Journal of Medicinal Chemistry (2025), pp. 117560-117560
Closed Access
Targeted Degradation of METTL3 Against Acute Myeloid Leukemia and Gastric Cancer.
Kyubin Hwang, Ju‐Hyeon Bae, Yoo-Lim Jhe, et al.
European Journal of Medicinal Chemistry (2024) Vol. 279, pp. 116843-116843
Closed Access | Times Cited: 3
Post‐Translational Modifications of RNA‐Modifying Proteins in Cellular Dynamics and Disease Progression
Yunfan Lin, Pei Lin, Ye Lu, et al.
Advanced Science (2024) Vol. 11, Iss. 44
Open Access | Times Cited: 3
Patent landscape of small molecule inhibitors of METTL3 (2020-present)
Zhixing Wu, Alexis R. Smith, Zhijian Qian, et al.
Expert Opinion on Therapeutic Patents (2024), pp. 1-16
Closed Access | Times Cited: 3
Recent advances in noncoding RNA modifications of gastrointestinal cancer
Tomoaki Hara, Sikun Meng, Yasuko Arao, et al.
Cancer Science (2024)
Open Access | Times Cited: 2
Therapeutic strategies to target the epitranscriptomic machinery
Denise Sighel, Eliana Destefanis, Alessandro Quattrone
Current Opinion in Genetics & Development (2024) Vol. 87, pp. 102230-102230
Open Access | Times Cited: 1
PROTAC delivery in tumor immunotherapy: Where are we and where are we going?
Yiyang Li, Yike Wu, Shugeng Gao, et al.
Journal of Controlled Release (2024) Vol. 378, pp. 116-144
Closed Access | Times Cited: 1
Therapeutic approaches targeting oncogenic proteins in myeloid leukemia: challenges and perspectives
Xing Yan, Yuan Yuan Kang, Ze Yan Zhang, et al.
Expert Opinion on Therapeutic Targets (2024)
Closed Access | Times Cited: 1
RNA methylation: where to from here for hematological malignancies?
Andrew A. Guirguis
Experimental Hematology (2024) Vol. 143, pp. 104694-104694
Closed Access
Page 1

Scroll to top